Bristol-based, Neuronostics Ltd, a leader in advanced digital biomarkers and EEG analysis, has announced a strategic commercial partnership with Nervus Ltd, known for its fast, accurate, and cost-effective EEG solutions. The collaboration will enhance access to EEG technology and innovative tools for analysis, aiming to reduce diagnostic delays and improve patient outcomes.
This partnership will directly benefit NHS Trusts, providing access to cutting-edge EEG diagnostics that streamline workflows, reduce waiting times, and support clinical decision-making. By integrating Neuronostics' BioEP technology with Nervus' advanced EEG systems, the solution promises comprehensive, high-quality diagnostic information to improve efficiency and patient care.
Professor John R. Terry, Managing Director at Neuronostics, said: “I’m delighted that Nervus and Neuronostics will work collaboratively on the challenge of epilepsy diagnosis. Working closely with both clinicians and people with suspected epilepsy, I have seen first-hand the significant impact that delays in accessing EEG services has. By embedding BioEP within the Nervus software we will ensure that clinicians have easy access to the best possible information to support their diagnostic decisions.”
Neuronostics and Nervus will also focus on building partnerships with NHS Trusts across the UK to accelerate the adoption of this innovative technology. By enabling access to the BioEP algorithm directly within Nervus software, the collaboration is poised to enhance patient care and streamline the diagnostic process.
